Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNB NASDAQ:RGNX NASDAQ:SDGR NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89BIO$10.49-1.5%$9.79$4.16▼$11.84$1.53B1.281.54 million shs1.31 million shsRGNXREGENXBIO$8.16-6.1%$8.96$5.04▼$15.36$409.31M1.06928,289 shs742,903 shsSDGRSchrodinger$21.45-0.9%$21.94$16.60▼$28.47$1.57B1.58928,386 shs962,275 shsTARSTarsus Pharmaceuticals$43.25+4.5%$41.85$20.08▼$57.28$1.82B0.8688,218 shs1.26 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89BIO0.00%-4.64%+4.90%+73.10%+20.85%RGNXREGENXBIO0.00%-5.99%-4.78%+37.37%-38.55%SDGRSchrodinger0.00%+2.09%+1.90%-16.70%-7.42%TARSTarsus Pharmaceuticals0.00%+10.39%+5.31%-12.18%+57.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89BIO2.1568 of 5 stars3.51.00.00.03.20.80.6RGNXREGENXBIO3.7869 of 5 stars3.41.00.04.60.03.30.6SDGRSchrodinger2.0399 of 5 stars3.41.00.00.02.41.70.6TARSTarsus Pharmaceuticals1.645 of 5 stars3.50.00.00.01.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89BIO 3.00Buy$26.43151.94% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63287.56% UpsideSDGRSchrodinger 2.75Moderate Buy$32.7552.68% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.6754.14% UpsideCurrent Analyst Ratings BreakdownLatest RGNX, TARS, ETNB, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $30.007/12/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.006/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.006/2/2025TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.005/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$72.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89BION/AN/AN/AN/A$3.34 per shareN/ARGNXREGENXBIO$83.33M4.91N/AN/A$5.24 per share1.56SDGRSchrodinger$207.54M7.58N/AN/A$5.78 per share3.71TARSTarsus Pharmaceuticals$233.67M7.78N/AN/A$5.87 per share7.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%8/6/2025 (Estimated)Latest RGNX, TARS, ETNB, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TARSTarsus Pharmaceuticals-$0.41N/AN/AN/A$95.81 millionN/A8/7/2025Q2 2025RGNXREGENXBIO-$1.13N/AN/AN/AN/AN/A8/4/2025Q2 2025ETNB89BIO-$0.49N/AN/AN/AN/AN/A7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/A5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89BION/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89BIO0.0618.0318.03RGNXREGENXBION/A2.932.93SDGRSchrodingerN/A3.453.45TARSTarsus Pharmaceuticals0.215.575.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89BION/ARGNXREGENXBIO88.08%SDGRSchrodinger79.05%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipETNB89BIO2.60%RGNXREGENXBIO12.79%SDGRSchrodinger8.60%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89BIO40145.98 million142.19 millionOptionableRGNXREGENXBIO37050.16 million43.75 millionOptionableSDGRSchrodinger79073.38 million67.07 millionOptionableTARSTarsus Pharmaceuticals5042.01 million38.25 millionOptionableRGNX, TARS, ETNB, and SDGR HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Tarsus Pharmaceuticals (TARS) and Abbott Laboratories (ABT)July 20 at 2:11 AM | theglobeandmail.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Jennison Associates LLCJuly 19 at 7:30 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up - Here's What HappenedJuly 18 at 12:03 PM | marketbeat.comWilliam Blair Issues Negative Forecast for TARS EarningsJuly 18 at 2:41 AM | americanbankingnews.comTarsus Pharmaceuticals: Making Big StridesJuly 17 at 11:30 AM | seekingalpha.comWilliam Blair Issues Pessimistic Estimate for TARS EarningsJuly 16, 2025 | marketbeat.comWilliam Blair Has Bearish Estimate for TARS FY2026 EarningsJuly 16, 2025 | americanbankingnews.comWhat is William Blair's Estimate for TARS FY2026 Earnings?July 15, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Consensus PT from AnalystsJuly 15, 2025 | americanbankingnews.comTarsus Pharmaceuticals Stock Price, Quotes and ForecastsJuly 13, 2025 | benzinga.comHot Tick Summer Is Here. Here’s What You Need to Know and How to Stay SafeJuly 12, 2025 | gizmodo.comGGrant GrossMendelsohn LLC Sells 26,143 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)July 12, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by AnalystsJuly 12, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Sells 12,401 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)July 5, 2025 | marketbeat.comTarsus Pharmaceuticals Inc Ordinary Shares - MorningstarJuly 2, 2025 | morningstar.comMTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Lisanti Capital Growth LLCJune 29, 2025 | marketbeat.comTarsus Pharmaceuticals Becomes Oversold (TARS)June 19, 2025 | nasdaq.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13, 2025 | investing.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13, 2025 | investing.comStocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS RatingJune 6, 2025 | msn.comTarsus Pharmaceuticals assumed with an Outperform at OppenheimerJune 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGNX, TARS, ETNB, and SDGR Company Descriptions89BIO NASDAQ:ETNB$10.49 -0.16 (-1.50%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$10.61 +0.12 (+1.14%) As of 07/18/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.REGENXBIO NASDAQ:RGNX$8.16 -0.53 (-6.10%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.28 +0.12 (+1.48%) As of 07/18/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Schrodinger NASDAQ:SDGR$21.45 -0.20 (-0.92%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$21.74 +0.29 (+1.33%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Tarsus Pharmaceuticals NASDAQ:TARS$43.25 +1.85 (+4.47%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$43.25 0.00 (0.00%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
